Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | GYS1 | P13807 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3887170 | 0.90 | THRA (0.46) | C5AR1CA12S1PR1THRATHRB | |
| SCHEMBL3883719 | 0.85 | CCNC (0.48) | C5AR1MEN1KMT2APTPN1HRH3 | |
| SCHEMBL3681581 | 0.84 | MEN1 (0.41) | C5AR1MEN1KMT2APTPN1HRH3 | |
| SCHEMBL7725141 | 0.83 | C5AR1 (0.55) | C5AR1MEN1KMT2APTPN1HRH3 | |
| SCHEMBL3686345 | 0.83 | MEN1 (0.40) | C5AR1MEN1KMT2APTPN1HRH3 | |
| SCHEMBL3686084 | 0.83 | C5AR1 (0.41) | C5AR1MEN1KMT2APTPN1HRH3 | |
| SCHEMBL3887753 | 0.83 | MEN1 (0.42) | C5AR1MEN1KMT2APTPN1HRH3 | |
| SCHEMBL7725535 | 0.83 | C5AR1 (0.57) | C5AR1MEN1KMT2APTPN1HRH3 | |
| SCHEMBL3887867 | 0.83 | C5AR1 (0.42) | C5AR1MEN1KMT2APTPN1HRH3 | |
| SCHEMBL3682347 | 0.83 | MEN1 (0.40) | C5AR1MEN1KMT2APTPN1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1477472-B1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2009-01-14 | — | — | EP | claimed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | claimed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | claimed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | claimed |
| EP-1477472-B1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | disclosed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-1068636-A4 | ULTRA-HIGH RESOLUTION LIQUID CRYSTAL DISPLAY ON SILICON-ON-SAPPHIRE | SHIMABUKURO RANDY L (US) | 2003-08-06 | — | — | EP | disclosed |
| EP-1068636-A1 | ULTRA-HIGH RESOLUTION LIQUID CRYSTAL DISPLAY ON SILICON-ON-SAPPHIRE | Shimabukuro, Randy L. (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999049503-A1 | ULTRA-HIGH RESOLUTION LIQUID CRYSTAL DISPLAY ON SILICON-ON-SAPPHIRE | SHIMABUKURO RANDY L (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | PTGER1, CYSLTR1, PTGS1 | C5AR1 282/4885MEN1 4756/4885KMT2A 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.